Takeda files second-line H pylori therapy in Japan
This article was originally published in Scrip
Executive Summary
Takedahas submitted an approval application in Japan for Lampion, a triple therapy for the eradication of gastro-intestinal Helicobacter pylori infections resistant to standard first-line triple therapy.